Creative Biolabs Released A Comprehensive CAR Design & Construction Service
As a biopharmaceutical company highly specialized in cancer treatment R&D, Creative Biolabs recently has launched a brand new CAR design & construction service, aiming at clearing the tumor without the toxicity of conventional treatments.
CAR T therapy, a novel immunotherapy, is an excellent example of the application of basic research to the clinic. In detail, CAR stands for chimeric antigen receptor or artificial T cell receptor, which is engineered elaborately and endowing an immune effector cell (T cell) with an arbitrary specificity via a monoclonal antibody.
“There are four generations in the CAR design development history. The original CAR-T or the first-generation CAR consists of the intracellular domain from the CD3 ζ- chain and the primary transmitter of signals from endogenous TCRs. To augment the antitumor efficacy of 1st-generation CARs, the 2nd-generation were designed to combine the intracellular signaling domains from various costimulatory protein receptors. And the 3rd-generation of CARs combined multiple signaling domains (e.g., CD3 ζ-CD28-41BB, CD3 ζ-CD28-OX40) to acquire further enhanced function. ” A scientist from Creative Biolabs said that.
“The previous CAR strategies are highly specific and useful in redirecting T cells targeting malicious cancer cells. The 4th-generation CAR-T is designed to shape the tumor environment by the inducible release of transgenic immune modifiers, such as IL-12, which augments T-cell activation, attracts and activates innate immune cells to eliminate antigen-negative cancer cells in the targeted lesion.
With a professional team and advanced platforms, Creative Biolabs inherits advantages of CAR T strategy to help researchers make scientific history fighting malicious cancers.
About Creative Biolabs
With more than a decade of exploration and expansion, Creative Biolabs provides current research and service capacity that covers the entire new drug discovery and development pipeline, ranging from early discovery, pre-clinical evaluations, cGMP manufacturing, to clinical trials. As an international cooperation, Creative Biolabs established offices all around the globe with more than 200 well-trained full-time scientists and technicians, who work closely with customers and research partners to develop new medicines for a better, healthier world. After years of pursuit for perfection, Creative Biolabs has established leadership in targeted immunotherapy and antibody-drug conjugate (ADC) development. They offer customers comprehensive one-stop-shop of all aspects in ADC research and evaluation, ranging from antigen selection, antibody production/optimization, payload-linker synthesis, ADC conjugation, to various stages of ADC characterization and pre-clinical evaluation.